Items tagged with Treatment
The start of a new international clinical trial to improve treatment for TB with anti-inflammatory agents (post)
-- The Experimental Tuberculosis Group at the IGTP has set up this trial, coordinated from Can Ruti, within the European project H2020 'SMA-TB'
-- The study will evaluate the efficacy and safety of adding acetylsalicylic acid or ibuprofen to the antibiotic treatments applied for tuberculosis
-- It is a phase II trial which will be carried out in South Africa and Georgia, two of the countries the WHO has in its sights to control this infectious disease
-- The trial has been prepared in the midst of the pandemic, with the added challenge of coordinating it with the restrictions and different stages of the epidemic in each of the countries involve
Call for expressions of interest: Data Curator for the Global individual patient data platform for drug-resistant TB treatment (post)
16 March 2021, Geneva | The World Health Organization Global Tuberculosis Programme has initiated a process for the establishment of Global individual patient data platform for drug-resistant tuberculosis treatment (DR-TB IPD). The DR-TB IPD is a shared platform and collaborative initiative to generate reliable evidence on drug-resistant TB treatment to inform future TB treatment guidelines and be available for researchers to analyse. The purpose of the DR-TB IPD is to facilitate pooling of individual patient data issued from researchers, local or national databases in the context of drug-resistant TB treatment and facilitate policy update, development and public health research. It will be supported by the WHO Global TB Programme and maintained by the selected Data Curator. Data Curator is the entity in charge of maintenance, curation and hosting of the DR-TB IPD.
CROI 2021: TB-related coverage (post)
2021 Conference on Retroviruses and Opportunistic Infections (CROI) was held virtually on 6-10 March 2021.
Building resilience needs to be central to treating drug-resistant TB (post)
A study published in The Lancet Global Health described distinct stages through drug-resistant TB (DR-TB) diagnosis and treatment from the point of view of patients with DR-TB and HIV in KwaZulu-Natal province, South Africa. The study emphasised that despite improvements in treatment, including shorter, all-oral regimens that include bedaquiline, DR-TB treatment remains lengthy, difficult, and life-changing for individuals.
Amid global pandemic, TB treatment innovation advances at an unprecedented pace (post)
PRETORIA (24 March 2021) — On World TB Day, as society reflects on how COVID-19 became the world’s most lethal infection in the span of a year, progress against tuberculosis (TB) can be found in the swift rollout of a short, all-oral regimen for highly drug-resistant TB infections.
Scientists find that binding iron improves the effect of the anti-TB drug bedaquiline (post)
Although TB killed nearly as many people as COVID-19 (approx. 1.8 million) in 2020, it did not receive as much media and public attention. The pandemic has proven that transmissible infection is indeed a global issue. TB remains a serious public health concern in Ireland, particularly with the presence of multi-drug resistant types and the numbers of complex cases here continuing to rise, with cases numbering over 300 annually.
Drug-resistant TB clinical trial ends enrolment early after positive initial data (post)
-- A clinical trial testing a shorter regimen for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early.
-- The trial, sponsored by MSF, has stopped randomising patients because of data which has indicated the trial regimen’s superior outcomes over existing regimens.
-- We hope the data, which will be submitted for peer review, will lead to WHO to change recommendations for MDR-TB treatment.
STAND clinical trial results published (post)
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal of Tuberculosis and Lung Disease.
Astellas and TB Alliance enter into a new collaborative research agreement to identify lead compounds for the treatment of TB (post)
TOKYO and NEW YORK (March 31, 2021) — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and TB Alliance (President and CEO: Mel Spigelman, M.D.), a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) today announced that they have entered into a new collaborative research (“Hit-to-Lead PJ”) agreement to identify lead compounds for the treatment of TB.
Call for expressions of interest: Expert(s) for conducting data synthesis and analysis on the use of new regimens for the treatment of DR-TB (post)
The World Health Organization (WHO) Global TB Program has initiated a process to update the consolidated guidelines on the treatment of drug-resistant TB (DR-TB). The WHO Global TB Program is seeking support from independent researchers, academic institutions or other entities with relevant expertise and experience in systematic review and statistical analysis to perform the synthesis and analysis of the available data on new DR-TB treatment regimens for the guideline update.
Page 56 of 108 · Total posts: 0
←First 55 56 57 Last→